Sumitomo Mitsui Trust Group Inc. Acquires 8,000 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Sumitomo Mitsui Trust Group Inc. raised its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.6% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 520,448 shares of the medical equipment provider’s stock after buying an additional 8,000 shares during the period. Sumitomo Mitsui Trust Group Inc.’s holdings in Zimmer Biomet were worth $46,799,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Rakuten Investment Management Inc. purchased a new stake in Zimmer Biomet during the 3rd quarter valued at $37,307,000. Sector Gamma AS boosted its position in Zimmer Biomet by 28.0% during the 3rd quarter. Sector Gamma AS now owns 113,478 shares of the medical equipment provider’s stock valued at $11,178,000 after buying an additional 24,847 shares during the period. SG Americas Securities LLC boosted its position in Zimmer Biomet by 29.2% during the 3rd quarter. SG Americas Securities LLC now owns 61,110 shares of the medical equipment provider’s stock valued at $6,019,000 after buying an additional 13,812 shares during the period. Border to Coast Pensions Partnership Ltd boosted its position in Zimmer Biomet by 6.5% during the 3rd quarter. Border to Coast Pensions Partnership Ltd now owns 360,462 shares of the medical equipment provider’s stock valued at $35,506,000 after buying an additional 22,104 shares during the period. Finally, National Pension Service boosted its position in Zimmer Biomet by 4.5% during the 3rd quarter. National Pension Service now owns 393,476 shares of the medical equipment provider’s stock valued at $38,757,000 after buying an additional 16,928 shares during the period. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Insider Transactions at Zimmer Biomet

In related news, SVP Lori Winkler sold 2,650 shares of Zimmer Biomet stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $94.66, for a total transaction of $250,849.00. Following the completion of the transaction, the senior vice president directly owned 10,224 shares of the company’s stock, valued at $967,803.84. This trade represents a 20.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.28% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

ZBH has been the subject of several analyst reports. Evercore raised shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and increased their price target for the company from $94.00 to $120.00 in a research report on Monday, January 5th. Wall Street Zen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Saturday, April 11th. Citigroup reaffirmed a “buy” rating on shares of Zimmer Biomet in a research report on Wednesday, February 11th. UBS Group reaffirmed a “sell” rating and issued a $89.00 target price on shares of Zimmer Biomet in a research report on Wednesday, February 11th. Finally, Wells Fargo & Company raised their target price on shares of Zimmer Biomet from $93.00 to $98.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 11th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $105.95.

Zimmer Biomet Trading Down 2.4%

NYSE:ZBH opened at $94.19 on Thursday. The company has a 50-day moving average price of $93.44 and a 200-day moving average price of $93.32. Zimmer Biomet Holdings, Inc. has a 12 month low of $84.59 and a 12 month high of $108.29. The company has a current ratio of 1.98, a quick ratio of 1.10 and a debt-to-equity ratio of 0.55. The stock has a market cap of $18.23 billion, a price-to-earnings ratio of 26.61, a P/E/G ratio of 1.97 and a beta of 0.61.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The company had revenue of $2.24 billion during the quarter, compared to analysts’ expectations of $2.22 billion. During the same period last year, the company posted $2.31 EPS. Zimmer Biomet’s revenue was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio (DPR) is 27.12%.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.